Actualités

Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.

Find insight on Johnson & Johnson, Rubber Industries, and more in the latest Market Talks covering health care.

Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided ... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

Investors didn't seem to think so after the company published it.

How do you find the best dividend stocks to buy? Income investors know there's no substitute for regular dividend increases over the long haul.

Wholesale inflation data cooled while major earnings season kicked off positively, lifting stocks across the board, today, July 15, 2026.

Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.

Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...

Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State

Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.

Find insight on Johnson & Johnson, Roche Holding, Novartis and more in the latest Market Talks covering health care.

Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.

All three major US stock indexes were up in late-morning trading Wednesday, as technology stocks led

Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.

Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...

Producer Inflation Cools in June

JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.

ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...

Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.

Walmart and Johnson & Johnson both beat estimates this quarter, but the way each giant is spending its capital tells two completely different stories about where defensive investing actually pays off right now.

Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expect

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

News of the day for July 15, 2026